# Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

> **NCT00116831** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 672 (actual)

## Conditions studied

- Atherosclerosis

## Interventions

- **DRUG:** Glipizide
- **DRUG:** rosiglitazone maleate

## Key facts

- **NCT ID:** NCT00116831
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2008-08
- **Final completion:** 2008-08
- **Target enrollment:** 672 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00116831

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00116831, "Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00116831. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*